0 2 min 7 mths

[ad_1]

childrenshealthdefense.org: Two-dose administration of Pfizer’s COVID vaccine offers very limited protection, if any, against the omicron variant, Pfizer CEO Albert Bourla said Monday in an interview on CNBC’s “Squawk Box.”

That’s a far cry from Bourla’s earlier claim that the two-dose shot was “100% effective.”

If a third or booster dose is given, the vaccine offers only “adequate protection” against hospitalization and death from omicrons and “less protection against infection,” Bourla said.

This latest admission by Bourla is “crucial to the Supreme Court mandate cases,” said Dr. Meryl Nass, as both employer and health care mandates only require the first two vaccinations.

“It’s hard to imagine how any mandates could stand,” said Nass, a practicing physician and a member of the Children’s Health Defense Scientific Advisory Committee.

Journalist Jordan Schachtel speculated that Bourla admitted the ineffectiveness of Pfizer’s vaccine against Omicron in support of the vaccine maker’s latest and upcoming product: an Omicron-specific vaccine.

Bourla told CNBC’s Meg Tirrell that Pfizer’s Omicron-specific vaccine will be ready by March.

Pfizer is estimated to have made $33.5 billion in sales from COVID vaccines in 2021, and the company expects similar results this year.

[ad_2]

Source link

Leave a Reply

Your email address will not be published.